CLTN.SW COLTENE Holding AG (SIX) down 7.06% at close 16 Jan 2026: market signals
CLTN.SW stock slid 7.06% to CHF54.00 at the market close on 16 Jan 2026 on the SIX in Switzerland, making it one of the day’s top losers. Volume spiked to 19,409 shares, about 3.09x the average, signaling heavy selling. Traders reacted to profit-taking near the 52-week high and a sharp intraday gap from CHF58.10 to CHF54.00. We review valuation, technicals, Meyka AI grade and short-term forecasts to frame trading and investment choices for COLTENE Holding AG (CLTN.SW).
CLTN.SW stock: market snapshot at close
COLTENE Holding AG (CLTN.SW) closed on the SIX at CHF54.00, down CHF4.10 or 7.06% on 16 Jan 2026. The session ranged between CHF53.70 and CHF57.00, with an opening print of CHF57.00 and a previous close of CHF58.10. Average 50-day price is CHF51.12, and 200-day price average is CHF55.58, so today’s close sits slightly below the longer-term average. Trading volume of 19,409 versus avg 6,280 shows elevated liquidity and outsized selling interest.
CLTN.SW stock: valuation and fundamentals
COLTENE reports EPS of CHF2.40 and a reported PE of 22.50 at the quoted price. Key ratios show price-to-sales 1.44 and price-to-book 3.86, while dividend per share is CHF2.50, implying a yield near 4.63% at current levels. Return metrics include ROE 14.37% and operating margin near 8.89%. Balance sheet metrics show debt-to-equity about 0.56 and a current ratio 1.47, which supports near-term liquidity. These fundamentals help explain why some investors treat CLTN.SW as an income plus growth holding in healthcare.
CLTN.SW stock: technical picture and short-term signals
Technically, CLTN.SW shows momentum divergence after reaching a year high CHF71.70 earlier. RSI sits at 68.72, MACD histogram is 0.10, and ADX 32.16 indicates a strong trend. Bollinger Bands middle is CHF53.24 with an upper band at CHF56.05, so today’s close near the middle band signals a pullback within an uptrend. Short-term support shows at the 50-day average CHF51.12 and stronger support near the year low CHF42.60. Traders should watch volume and RSI for confirmation of further downside or a rebound.
CLTN.SW stock: sector context and peer comparison
CLTN.SW trades in the Healthcare sector on the SIX, where the sector average PE is 33.52. COLTENE’s reported PE of 22.50 is below the sector average, suggesting relative valuation modesty. The healthcare group has shown 1.41% 3-month performance on average, while CLTN.SW is +15.14% over three months. Relative to peers in Medical – Instruments & Supplies, COLTENE sits at mid-cap scale with market cap around CHF322.67M, which can increase sensitivity to flows compared with larger names like Roche or Novartis.
CLTN.SW stock: Meyka AI grade and model forecast
Meyka AI rates CLTN.SW with a score out of 100: 67.36 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of CHF59.38, a quarterly price of CHF61.46, and a 1-year projection of CHF47.58. The monthly forecast implies upside of 9.96% versus today; the 1-year forecast implies downside of 11.89%. Forecasts are model-based projections and not guarantees.
CLTN.SW stock: risks and near-term catalysts
Key near-term catalysts include the next earnings announcement on 06 Mar 2026, product rollout news, and regional dental demand trends. Risks include inventory cycles (days of inventory 177.27), margin sensitivity, and a payout ratio above 100% which could pressure dividends if profits slip. External macro risks for Swiss medical suppliers include currency swings, supplier cost inflation, and slower dental capex in key markets. Monitor company news and the investor relations page for confirmations source.
Final Thoughts
CLTN.SW stock’s slide to CHF54.00 at the market close on 16 Jan 2026 is a clear short-term negative, but the move sits inside a broader uptrend from recent months. Valuation metrics show a mid-range PE of 22.50 and a generous cash dividend of CHF2.50 per share, which supports yield-oriented holders. Meyka AI’s grade is B (score 67.36, HOLD) and the model projects a near-term monthly target of CHF59.38, implying a 9.96% upside from today. The quarterly projection of CHF61.46 implies 13.81% upside, while the 12-month projection of CHF47.58 implies downside of 11.89%. These model outputs and the stock’s elevated intraday volume argue for a cautious approach: traders may find short-term bounce opportunities, while investors should weigh dividend yield, inventory dynamics and upcoming earnings before increasing exposure. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.
FAQs
What caused the CLTN.SW stock drop on 16 Jan 2026?
CLTN.SW stock fell 7.06% on 16 Jan 2026 due to heavy profit-taking, a volume spike to 19,409 and a pullback from recent highs. No specific company announcement drove the move; technical selling and rotation in the healthcare group were the likely drivers.
Is CLTN.SW stock a buy after the decline?
Meyka AI currently scores CLTN.SW as B (HOLD). The stock offers a dividend yield near 4.63%, but the 12-month model projects CHF47.58, implying downside. Consider earnings, liquidity needs and risk tolerance before buying.
What are the key financials to watch for CLTN.SW stock?
Monitor EPS (CHF2.40), PE (22.50), dividend per share (CHF2.50), inventory turn and cash conversion cycle. Watch debt-to-equity (0.56) and operating margin changes around the next earnings release on 06 Mar 2026.
How does the Meyka AI forecast affect CLTN.SW stock outlook?
Meyka AI’s model projects monthly CHF59.38 and quarterly CHF61.46, implying near-term upside. These are statistical projections, not guarantees. Use them alongside fundamentals, sector trends and the upcoming earnings report.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
